Monday, July 5, 2021

Pumped by a big year for its flu shots, Sanofi lays out €600M for new vaccine manufacturing plant

Sanofi may not be at the forefront in COVID-19 vaccines, but in influenza, it’s the biggest player—and as of now, getting even bigger.

The French drugmaker plans to splash out €600 million to build a new flu vaccine factory in Toronto to increase supply of its Fluzone High-Dose vaccine. The plant will turn out the vaccine, which contains four times more antigen than standard-dose vaccines, for Canada, the U.S. and Europe.

Slated to open in 2026, the site will also help with influenza pandemic preparedness, a spokesman said. The manufacturing expansion is “part of our overall growth strategy of which vaccines will be a major contributor,” he added. 

In a statement, Sanofi CEO Paul Hudson said the company is looking “ahead to address the fast-growing demand” for its high-dose shot, which has “demonstrated clinical superiority against standard-dose vaccines.” The high-dose vaccine “provides a long-term competitive advantage” for the company, and the new factory will help supply more doses where they’re needed, he added.

RELATED: Sanofi, despite COVID-19, sees early gains from CEO Hudson’s strategy revamp 

Amid the COVID-19 pandemic, Sanofi’s flu vaccine business has soared. Last year, the company’s influenza shots generated nearly €2.5 billion in worldwide sales, a 38% increase from 2019 at constant exchange rates. High demand and a “differentiated portfolio,” which includes the high-dose shot, drove growth, Sanofi said. Sanofi’s high-dose shot targets four flu strains.

Vaccines are a top priority under Hudson’s strategy for the drugmaker’s long-term growth, alongside its immunology blockbuster Dupixent. 

Early in the COVID-19 pandemic, Sanofi teamed up with GlaxoSmithKline to develop an adjuvanted recombinant DNA vaccine, but the program hit a setback last year that forced a significant delay. Now, Sanofi and GSK are testing a reformulated shot and say they could have one ready to go by late 2021. 

RELATED: After Pfizer deal, Sanofi offers a hand to Johnson & Johnson for COVID-19 vaccine production 

While that program is advancing, Sanofi has offered manufacturing help to Pfizer and Johnson & Johnson. In late January, the company pledged to produce 100 million doses of the Pfizer/BioNTech mRNA shot for the European market in 2021.  

Then, a month later, Sanofi said it would allow J&J access to a site in France for formulation and vial filling. The site can turn out 12 million doses per month, Sanofi said at the time.

Source link

Stay Connected


Latest Articles

Covid’s second wave proves lethal for pregnant women

At SVP Hospital in Ahmedabad – one of the major Covid-19 hospitals of the city – 148 pregnant women with Covid-19 infection were admitted...

7 Tips to Keep Your Gut Healthy

This is common to say health (and illness) starts in your gut. If you have poor gut health, you’ll experience anything from wrinkled skin, to...

SII making first batch of Covovax: Poonawalla

The first batch of Covovax, a Covid-19 vaccine developed by Novavax Inc, is being manufactured at the Serum Institute of India's Pune facility, SII...

Sputnik V is safest among all Covid-19 vaccines, no deaths recorded: Buenos Aires study

A study by the Buenos Aires Ministry of Health to monitor the safety of the Sputnik V vaccine against Covid-19 confirmed on Thursday that...

Telangana caps Covid treatment charges in private hospitals

Hyderabad: The government of Telangana on Wednesday issued orders fixing treatment and investigation charges for Covid-19 in private hospitals.The state government, which had capped...